Fig. 3From: High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myelomaBCMA-CD38 CAR-T cells had potent activity against extramedullary lesions in MM patients. A - D The extramedullary lesions of patient 4 (A), 8 (B), 12 (C) and 15 (D) before and 2 months after BCMA-CD38 CAR-T infusionBack to article page